ImmuCell Corp (ICCC) stock
ICCCNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 12/3021% above fair value
$10.75+0.53 (+5.19%)
Close on Nov 13, 2026Market cap $97.63MP/E 53.8Yield –
ImmuCell total assets
Total assets on the balance sheet at the end of each period.
ImmuCell's total assets was $47.96M at Sep 30, 2026. For fiscal 2025 it was $42.53M, down 5.7% from the year before. Over ten years it grew 11.3% a year on average. The highest annual figure on record is $45.10M in fiscal 2024.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $42.53M | -5.7% |
| FY2024 | Dec 31, 2024 | $45.10M | +3.0% |
| FY2023 | Dec 31, 2023 | $43.81M | -2.3% |
| FY2022 | Dec 31, 2022 | $44.86M | +0.9% |
| FY2021 | Dec 31, 2021 | $44.47M | +10.2% |
| FY2020 | Dec 31, 2020 | $40.35M | +4.3% |
| FY2019 | Dec 31, 2019 | $38.69M | +18.2% |
| FY2018 | Dec 31, 2018 | $32.73M | -4.6% |
| FY2017 | Dec 31, 2017 | $34.30M | +38.9% |
| FY2016 | Dec 31, 2016 | $24.70M | +69.9% |
| FY2015 | Dec 31, 2015 | $14.54M | +31.6% |
| FY2014 | Dec 31, 2014 | $11.05M | +0.8% |
| FY2013 | Dec 31, 2013 | $10.96M | -0.6% |
| FY2012 | Dec 31, 2012 | $11.03M | +0.4% |
| FY2011 | Dec 31, 2011 | $10.99M | +2.2% |
| FY2010 | Dec 31, 2010 | $10.75M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $47.96M | +12.8% |
| Q2 FY2026 | Jun 30, 2026 | $46.63M | +9.6% |
| Q1 FY2026 | Mar 31, 2026 | $44.11M | -3.3% |
| Q4 FY2025 | Dec 31, 2025 | $42.53M | -5.7% |
| Q3 FY2025 | Sep 30, 2025 | $42.53M | -4.3% |
| Q2 FY2025 | Jun 30, 2025 | $42.53M | +1.6% |
| Q1 FY2025 | Mar 31, 2025 | $45.62M | +6.0% |
| Q4 FY2024 | Dec 31, 2024 | $45.10M | +3.0% |
| Q3 FY2024 | Sep 30, 2024 | $44.45M | -0.2% |
| Q2 FY2024 | Jun 30, 2024 | $41.86M | -4.9% |
| Q1 FY2024 | Mar 31, 2024 | $43.05M | -0.2% |
| Q4 FY2023 | Dec 31, 2023 | $43.81M | -2.3% |
| Q3 FY2023 | Sep 30, 2023 | $44.55M | -4.0% |
| Q2 FY2023 | Jun 30, 2023 | $44.01M | -4.3% |
| Q1 FY2023 | Mar 31, 2023 | $43.12M | -7.7% |
| Q4 FY2022 | Dec 31, 2022 | $44.86M | +0.9% |
| Q3 FY2022 | Sep 30, 2022 | $46.40M | +4.9% |
| Q2 FY2022 | Jun 30, 2022 | $45.98M | +5.2% |
| Q1 FY2022 | Mar 31, 2022 | $46.70M | +17.9% |
| Q4 FY2021 | Dec 31, 2021 | $44.47M | +10.2% |
| Q3 FY2021 | Sep 30, 2021 | $44.23M | +10.6% |
| Q2 FY2021 | Jun 30, 2021 | $43.73M | +7.5% |
| Q1 FY2021 | Mar 31, 2021 | $39.62M | -1.1% |
| Q4 FY2020 | Dec 31, 2020 | $40.35M | +4.3% |
| Q3 FY2020 | Sep 30, 2020 | $39.99M | +2.9% |
| Q2 FY2020 | Jun 30, 2020 | $40.66M | +3.2% |
| Q1 FY2020 | Mar 31, 2020 | $40.05M | -1.0% |
| Q4 FY2019 | Dec 31, 2019 | $38.69M | +18.2% |
| Q3 FY2019 | Sep 30, 2019 | $38.85M | +16.9% |
| Q2 FY2019 | Jun 30, 2019 | $39.41M | +20.4% |
| Q1 FY2019 | Mar 31, 2019 | $40.48M | +18.0% |
| Q4 FY2018 | Dec 31, 2018 | $32.73M | +8.1% |
| Q3 FY2018 | Sep 30, 2018 | $33.24M | +18.4% |
| Q2 FY2018 | Jun 30, 2018 | $32.74M | +29.2% |
| Q4 FY2017 | Dec 31, 2017 | $34.30M | +38.9% |
| Q3 FY2017 | Sep 30, 2017 | $30.29M | – |
| Q2 FY2017 | Jun 30, 2017 | $28.06M | – |
| Q1 FY2017 | Mar 31, 2017 | $25.33M | – |
| Q4 FY2016 | Dec 31, 2016 | $24.70M | – |
See a number that looks wrong?